XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets
XOMA Corporation (XOMA)
Last xoma corporation earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xoma.com/investor-relations
Company Research
Source: GlobeNewswire
EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L. One of the assets, NIR178, is being developed by Novartis as a novel checkpoint inhibitor for the treatment of solid tumors. Five of the assets are being developed by Palobiofarma. “We are impressed by Palobiofarma’s expertise in adenosine receptor biology and what they have achieved. It’s unusual today to discover a private company that has three distinct compounds in Phase 2 development and three additional compounds in Phase 1 clinical studies. We are particularly attracted to NIR178, which is being developed by Novartis as a potential novel immuno-oncology agent for the treatment of multiple solid tumors,” said Jim Neal, Chief Executive Officer at XOMA. “Palobiofarma’s portfolio covers all four adenosine receptor sub-types. Among these
Show less
Read more
Impact Snapshot
Event Time:
XOMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XOMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XOMA alerts
High impacting XOMA Corporation news events
Weekly update
A roundup of the hottest topics
XOMA
News
- XOMA Corporation Announces Closing of Tender Offer [Yahoo! Finance]Yahoo! Finance
- XOMA Corporation Announces Closing of Tender OfferGlobeNewswire
- XOMA Declares Quarterly Preferred Stock DividendsGlobeNewswire
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. [Yahoo! Finance]Yahoo! Finance
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.GlobeNewswire
XOMA
Earnings
- 11/7/23 - Miss
XOMA
Analyst Actions
- 2/16/24 - HC Wainwright
XOMA
Sec Filings
- 4/3/24 - Form 8-K
- 4/2/24 - Form ARS
- 4/2/24 - Form DEFA14A
- XOMA's page on the SEC website